KCT0009469招募中Unknown
A 12-week, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of EEFE on cognitive function improvement
Ewha Womens University0 个研究点目标入组 80 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55(Year) 至 79(Year)（—）
- 性别
- All
入选标准
- •1) Those who agree to participate in this study before the test begins and submit a completed informed consent form
- •2) Men and women aged 55 to under 80 years old
- •3) Those who complain of subjective cognitive decline
排除标准
- •1) Individuals suspected of having dementia as a result of a neuropsychological examination
- •2) Those diagnosed with any Axis I psychiatric disorder
- •3) Those with major medical or surgical diseases requiring immediate treatment, according to their medical history, physical examination, neurological examination, or clinical pathology examination
- •4) Individuals with contraindications to MRI
- •5) Individuals with the following diseases:
- •? Malignant tumors, severe cerebrovascular disease, heart disease, or neuropsychiatric disorders requiring treatment
- •? A history of traumatic brain injury accompanied by loss of consciousness or convulsions within the past six months
- •? A history of acute stroke within the last three months
- •? Uncontrolled hypertension, diabetes, thyroid dysfunction, or kidney failure
- •? Severe hearing or vision impairment that makes functional evaluation impossible
- •6) Individuals who have taken anti-dementia drugs or brain metabolism enhancers in the past month
- •7) Those who have taken psychotropic drugs within the past three months
- •8) Those who have taken any drug or health functional food related to cognitive function, or foods similar to the test material within the past month
- •9) Those who have participated in other clinical trials (including human trials) within a month of the start of this human trial
- •10) Those with hypersensitivity to the ingredients in the investigational products or a history of severe allergic reactions
- •11) Individuals whom the principal investigator deems unsuitable for participation due to other reasons
研究者
相似试验
已完成
不适用
Clinical trial for the evaluation of the efficacy and safety of DuolacProAP 4 on the reduction of blood acetaldehyde and alcohol after alcohol consumptioKCT0005361Cell Biotech54
进行中（未招募）
1 期
A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury - C10953/3067/ES/MPatients with excessive Sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI)MedDRA version: 12.0Level: LLTClassification code 10060690Term: Traumatic brain injuryMedDRA version: 12.0Level: LLTClassification code 10015595Term: Excessive daytime sleepinessEUCTR2009-014545-83-FRCephalon Inc.620
进行中（未招募）
不适用
A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury - C10953/3067/ES/MPatients with excessive Sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI)MedDRA version: 12.0Level: LLTClassification code 10060690Term: Traumatic brain injuryMedDRA version: 12.0Level: LLTClassification code 10015595Term: Excessive daytime sleepinessEUCTR2009-014545-83-CZCephalon Inc.620
招募中
不适用
A 12-week, randomized, double-blind, placebo-controlled human application trial to evaluate the efficacy and safety of ACP_01 on skin wrinkle improvement and moisturizingKCT0007720Daehan Chemtech Co., Ltd100
进行中（未招募）
1 期
A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury - C10953/3067/ES/MEUCTR2009-014545-83-DECephalon Inc.620